CalAmp (Nasdaq: CAMP), an advanced technology solutions company, has signed a strategic collaboration with Cryoport (Nasdaq: CYRX) (Nasdaq: CYRXW), a temperature-controlled logistics company dedicated to the life sciences industry.
It was reported yesterday that the collaboration is aimed at developing a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments. This research and development collaboration is aimed at improving the protection and preservation of critical life science shipments, which demonstrates CalAmp's continued momentum in the supply chain visibility market and Cryoport's commitment to providing the most advanced best-in-class, data-driven solutions to its biopharmaceutical client base.
Along with CalAmp, Cryoport is exploring an advanced supply chain visibility service that will monitor, in real-time, environmental readings for regenerative medicine product shipments using Bluetooth sensor technology. If successful, the combination of the Cryoport Express Shippers and the Cryoportal Logistics Management Platform, coupled with CalAmp's new-to-market SC iOn Tag Bluetooth sensor technology and SC iOn Command platform, is to allow Cryoport to offer another advanced logistics solution that would pro-actively manage supply chain visibility across multi-mode global shipping routes.
GSK secures Japan Orphan Drug status for lung cancer ADC
TheraCryf advances lead addiction programme to final preclinical stage
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
Innovent Biologics reports first participant dosed in tigulixostat Phase 3 study
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
Humacyte prices USD20m registered direct offering
Curia expands Glasgow manufacturing capacity and enhances CLD platform
Congruence Therapeutics secures USD39.5m financing
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Mirecule expands collaboration with Sanofi to advance FSHD therapy
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics